CARDOZA GEORGE 4
4 · SOPHiA GENETICS SA · Filed Apr 3, 2026
Research Summary
AI-generated summary of this filing
SOPHiA GENETICS (SOPH) CFO George Cardoza Receives RSU & Option Awards
What Happened
George Cardoza, Chief Financial Officer of SOPHiA GENETICS SA (SOPH), was granted equity on April 2, 2026: 112,936 restricted stock units (RSUs) and 164,671 derivative awards (stock option-type award). Both grants are reported at an acquisition price of $0 (they are awards, not open-market purchases), for a combined total of 277,607 units. These are time-based grants that vest over multi-year schedules rather than immediately tradable shares.
Key Details
- Transaction date: April 2, 2026; Form filed April 3, 2026 (timely filing).
- Reported acquisition price: $0 for both awards (standard for grant reporting).
- Grant amounts: 112,936 RSUs (F1) and 164,671 derivative/option awards (F2); total 277,607 units.
- Vesting (RSUs, F1): 25% vests April 2, 2027; remaining 75% vest in equal quarterly installments through April 2, 2030.
- Vesting (options/derivative, F2): 25% vests April 2, 2027; remaining vests in equal monthly installments through April 2, 2030.
- Shares owned after transaction: not specified in the provided filing excerpt.
- No 10b5-1 plan, tax withholding, sale, or late-filing flags noted in the filing excerpt.
Context
RSUs and option-style awards are common executive compensation designed to retain executives — they do not represent immediately tradable shares until vested (or exercised for options). Because these are grants (not purchases or sales), they are neutral in terms of immediate bullish/bearish signaling; they reflect compensation rather than an investment decision. The staged vesting means the awards will convert to exercisable/owned shares over the 2027–2030 period if the CFO remains employed.
Insider Transaction Report
- Award
Ordinary Shares
[F1]2026-04-02+112,936→ 112,936 total - Award
Share Option (Right to Buy)
[F2]2026-04-02+164,671→ 164,671 totalExercise: $5.04Exp: 2036-04-02→ Ordinary Shares (164,671 underlying)
Footnotes (2)
- [F1]Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan. Each RSU represents a contingent right to receive one ordinary share of the Issuer, subject to the Reporting Person's continued service with the Issuer through each applicable vesting date. 25% of the RSUs will vest on April 2, 2027, and the remaining 75% will vest in equal quarterly installments through April 2, 2030.
- [F2]The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2027, and then in equal monthly installments through April 2, 2030.